Open AccessBrain amyloid in preclinical Alzheimer's disease is associated with increased driving risk
Author(s) -
Ott Brian R.,
Jones Richard N.,
Noto Richard B.,
Yoo Don C.,
Snyder Peter J.,
Bernier Justine N.,
Carr David B.,
Roe Catherine M.
Publication year - 2016
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2016.10.008
Subject(s) - positron emission tomography , standardized uptake value , amyloid (mycology) , disease , medicine , cognition , alzheimer's disease , neuroimaging , psychology , cognitive decline , neuroscience , pathology , dementia
Postmortem studies suggest that fibrillar brain amyloid places people at higher risk for hazardous driving in the preclinical stage of Alzheimer's disease (AD). Methods We administered driving questionnaires to 104 older drivers (19 AD, 24 mild cognitive impairment, and 61 cognitive normal) who had a recent 18 F‐florbetapir positron emission tomography scan. We examined associations of amyloid standardized uptake value ratios with driving behaviors: traffic violations or accidents in the past 3 years. Results The frequency of violations or accidents was curvilinear with respect to standardized uptake value ratios, peaking around a value of 1.1 (model r 2 = 0.10, P = .002); moreover, this relationship was evident for the cognitively normal participants. Discussion We found that driving risk is strongly related to accumulating amyloid on positron emission tomography, and that this trend is evident in the preclinical stage of AD. Brain amyloid burden may in part explain the increased crash risk reported in older adults.